Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Real-time Quote. Real-time Tradegate - 02/23 03:05:53 pm
67.005 EUR   -1.70%
07:08a UCB FULL YEAR R : UCB demonstrates continued top and …
02/16 UCB : Transparency notification
02/09 UCB : Transparency notifications
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on UCB SA
07:08a UCB FULL YEAR REPORT 2016 : UCB demonstrates continued top and …
02/16 UCB : Transparency notification
02/09 UCB : Transparency notifications
02/08 UCB : Transparency notifications
01/25 UCB : Transparency notifications
01/19 UCB : files BRIVIACT® (brivaracetam) CV in the U.S. as …
01/19 UCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy &h..
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency Notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/06 Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
01/05 DERMIRA : Elects Emmanuel Caeymaex to Board of Directors
2016 DERMIRA,INC. (NASDAQ : DERM) Files An 8-K Departure of Directors or Certain Offi..
2016 UCB : Second CIMZIA (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy..
2016 UCB : Family Epilepsy Scholarship Program Announces 2016 Recipients
2016 UCB : Juno Biomedical Moving Forward with Regenerative Stroke Treatment
2016 UCB : The Lancet Publishes First Head-to-Head Study of Cimzia® (certolizumab peg..
2016 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU C..
2016 UCB : Patent Issued for Method for Producing Protein (USPTO 9476081)
2016 UCB : continues its growth path
2016 UCB : Transparency notification
2016 UCB : Transparency notification
2016 UCB : Transparency notification
2016 UCB : CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpo..
2016 UCB : Opens Solution Accelerator at Georgia Tech Technology Square
2016 UCB : and Amgen announce U.S. FDA acceptance of biologics licence application fo..
2016 UCB : Transparency notification
2016 UCB : receives positive EU CHMP opinion for CIMZIA® (certolizumab pegol) AutoCli..
2016 UCB : Results from phase 3 Frame study of romosozumab showed significant reducti..
2016 UCB : Transparency notification
2016 UCB : Transparency notifications
2016 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
2016 UCB : Transparency notification
2016 UCB : Transparency notification
2016 UCB : U.S. District Court confirms validity of patent for UCB's Vimpat®
2016 AMPHASTAR PHARMACEUTICALS : Purchases International Medication Systems (UK) Limi..
2016 UCB : continues to deliver on its growth strategy
2016 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
2016 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
2016 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
2016 UCB : bimekizumab demonstrates positive results in early development in patients..
2016 UCB : commitment to addressing real world patient needs on display at the Annual..
2016 UCB : BRIVIACT® now available in U.S. pharmacies for epilepsy patients living wi..
2016 UCB : Patent Issued for Systems for Automatically Administering Medication (USPT..
2016 UCB FIRST THREE MONTHS INTERIM REPOR :
2016 UCB : ex-dividend day for annual dividend
2016 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
2016 UCB : shareholder meeting today
2016 UCB FIRST THREE MONTHS INTERIM REPOR :
2016 UCB : Patent Issued for Protein Purification (USPTO 9309280)
2016 UCB : Patent Issued for Chiral Intermediate, Process for Producing the Same and ..
2016 UCB : Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab Wit..
2016 AMGEN : and UCB present positive data at ENDO 2016 comparing romosozumab with te..
2016 UCB : Acquisition of own shares April 1, 2016
2016 UCB : Amgen and UCB present positive data at ENDO 2016  comparing romosozumab wi..
2016 UCB : Acquisition of own shares March 1, 2016
2016 UCB : Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evalua..
2016 UCB : Nominations for new members of UCB's Board of Directors
2016 UCB : Convening notice to attend the general meeting of shareholders
2016 UCB : Nominations for new members of UCB's Board of Directors
2016 UCB : Announces Results from First Head-to-Head study of Cimzia® (certolizumab p..
2016 UCB : and Amgen announce positive topline results from phase 3 study evaluating ..
2016 GLENMARK PHARMACEUTICALS : Wins usfda nod for epilepsy drug
2016 Pharma crusader takes India's drug regulators to court
2016 UCB : with progress on its growth path delivering value to patients and sharehol..
2016 UCB : And Amgen Announce Positive Topline Results From The Phase 3 Study Of Romo..
2016 UCB : and Baylor College of Medicine launch strategic alliance in neurodegenerat..
2016 UCB : Executive Committee welcomes a new member
2016 UCB : new epilepsy drug BRIVIACT® receives EU approval
2016 UCB : Transparency notification
2015 Lannett to buy UCB unit to boost speciality generic drugs portfolio
2015DJLANNETT : to Acquire UCB's Kremers Urban Unit
1  2  3  4  5Next
Advertisement
Financials (€)
Sales 2016 4 069 M
EBIT 2016 754 M
Net income 2016 476 M
Debt 2016 898 M
Yield 2016 1,78%
P/E ratio 2016 25,84
P/E ratio 2017 21,19
EV / Sales 2016 3,50x
EV / Sales 2017 3,20x
Capitalization 13 333 M
More Financials
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 77,0 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA11.07%14 075
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results